Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer: a Multicentric Retrospective Cohort Study (METABREC)

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier. There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain. The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019

• All types of neoadjuvant treatment followed by surgery, primary surgery or salvage surgery.

• Adenocarcinoma or squamous cell carcinoma histology

Locations
United States
Texas
MD Anderson Cancer Center
NOT_YET_RECRUITING
Houston
Other Locations
Belgium
Universitair ziekenhuis Gent
NOT_YET_RECRUITING
Ghent
France
Centre Hospitalier régional Universitaire de Lille
NOT_YET_RECRUITING
Lille
Ireland
Saint James Hospital
NOT_YET_RECRUITING
Dublin
Netherlands
Amsterdam UMC
RECRUITING
Amsterdam
Zuyderland MC
NOT_YET_RECRUITING
Heerlen
Erasmus MC
NOT_YET_RECRUITING
Rotterdam
Sweden
Karolinska Institutet
RECRUITING
Stockholm
Contact Information
Primary
Lieven P Depypere, PhD
lieven.depypere@uzleuven.be
+32 16 346820
Backup
Johnny Moons, Msc
johnny.moons@uzleuven.be
+32 16 346820
Time Frame
Start Date: 2020-06-02
Estimated Completion Date: 2025-03-31
Participants
Target number of participants: 10000
Related Therapeutic Areas
Sponsors
Leads: Universitaire Ziekenhuizen KU Leuven

This content was sourced from clinicaltrials.gov